Nestlé Health Science is a globally leading health nutrition science company and a wholly-owned subsidiary of Nestlé Group, specializing in medical nutrition, health supplements, and specialized foods. Headquartered in Vevey, Switzerland, it operates 15 production facilities worldwide and achieved revenue of CHF 13 billion (approx. $14 billion) in 2024. With operations across 150 countries, the company maintains absolute market leadership through cutting-edge scientific research, pharmaceutical-grade quality standards, and a comprehensive professional distribution network.
Strengths: Nestlé Health Science's core strengths are its globally leading scientific research capabilities with substantial R&D investment and strong clinical evidence, pharmaceutical-grade quality control standards ensuring product safety and efficacy, and extensive professional distribution networks covering hospitals and medical institutions worldwide.
Weaknesses: The company faces limitations including relatively narrow specialization in professional health nutrition with limited mass market recognition, vulnerability to increasingly stringent global regulatory requirements, and significant competitive pressures in the high-margin health nutrition sector.

Abbott Laboratories is a global healthcare leader with a leading nutrition business specializing in infant formula, adult nutrition, and medical foods. Headquartered in Chicago, USA, it operates 30+ production facilities globally and achieved total revenue of $43 billion in 2024, with nutrition products contributing approximately $8 billion. With operations across 160 countries, Abbott maintains its leadership through strong scientific research, extensive medical professional endorsement, and pharmaceutical-grade quality standards.
Strengths: Abbott's core strengths are its globally leading scientific research capabilities with annual R&D investment exceeding $2.5 billion, extensive medical professional endorsement and powerful hospital channel network, and pharmaceutical-grade quality control standards ensuring product safety and efficacy.
Weaknesses: The company's weaknesses include the relatively limited proportion of nutrition business accounting for only 19% of total revenue, vulnerability to increasingly stringent global regulatory requirements, and intensifying competition in both domestic and international nutrition markets.

Danone Nutricia is a global leader in specialized nutrition, part of the Danone Group, focusing on infant formula, medical nutrition, and adult specialized nutrition products. Headquartered in the Netherlands with operations across 120 countries, it operates 20 production facilities worldwide and generated €9 billion in revenue in 2024. The company maintains its leadership position through strong scientific research, extensive medical professional endorsement, and pharmaceutical-grade quality standards in specialized nutrition.
Strengths: Nutricia's core strengths are its globally leading position in specialized nutrition with powerful brands like Aptamil, strong medical professional endorsement and extensive hospital channel network, and pharmaceutical-grade quality control standards supported by substantial clinical evidence.
Weaknesses: The company faces challenges including intensifying competition in the infant nutrition and medical nutrition sectors, vulnerability to increasingly stringent global regulatory requirements, and pressure from raw material cost fluctuations and geopolitical risks.

Glanbia plc is a leading global nutrition company headquartered in Ireland, specializing in nutritional ingredients, sports nutrition, and cheese products. With operations across 35 countries and 30+ production facilities worldwide, the company reported €5.5 billion in revenue in 2024. Glanbia maintains its significant market position through its dual B2B and B2C business model, advanced whey protein technology, and stringent quality control standards in the global nutrition industry.
Strengths: Glanbia's core strengths are its global leadership in whey protein and nutritional ingredients technology, unique dual business model combining B2B ingredients and B2C branded products, and stringent quality control standards with multiple international certifications.
Weaknesses: The company faces challenges including limited consumer brand recognition despite strong B2B presence, vulnerability to raw material price fluctuations in the dairy market, and intensifying competition in both ingredients and branded nutrition sectors.

Amway Corp. is a global leader in the health and wellness industry, renowned for its direct selling business model and Nutrilite brand of vitamins and dietary supplements. Headquartered in Ada, Michigan, it operates 10 production facilities worldwide and generated approximately $8.5 billion in revenue in 2024. With operations across 55 countries and territories, Amway maintains its market position through its unique direct selling network, stringent quality control systems, and continuous product innovation in nutritional supplements.
Strengths: Amway's core strengths are its unique global direct selling network with approximately 500,000 active distributors, strong in-house manufacturing capabilities with strict quality control from raw materials to finished products, and established brand equity particularly in nutritional supplements through its flagship Nutrilite brand.
Weaknesses: The company faces challenges including regulatory pressures and public skepticism associated with its direct selling model globally, intensifying competition from both traditional and e-commerce health product retailers, and the ongoing challenge of adapting its traditional business model to digital transformation trends.

Inner Mongolia Yili Industrial Group Co., Ltd. is China's largest dairy company, headquartered in Hohhot, Inner Mongolia. The company's business spans the full range of dairy products including liquid milk, infant formula, yogurt, and ice cream, achieving ¥126.2 billion revenue in 2023 and maintaining its position among the global top 5 dairy producers. Through 3,000+ partner farms and 80+ production bases, Yili has established a complete industrial chain system, exporting to 60+ countries worldwide.
Strengths: Holds absolute leadership in Chinese dairy market with extremely high brand recognition. Established complete industrial chain control from pasture to retail ensuring product quality management. Maintains deeply penetrated distribution network with full-channel coverage capability. Demonstrates outstanding continuous innovation capacity with highly diversified product portfolio.
Weaknesses: Faces raw material cost fluctuations and price increase pressures. Experiences intensifying competition in domestic dairy market. Confronts product transformation challenges from diversified and upgrading consumer demands. International expansion still lags behind global dairy giants requiring further development.

Perrigo Company plc is a leading global provider of store-brand health products headquartered in Dublin, Ireland. Operating in 40+ countries, it specializes in nutritional supplements, infant formula, and medical nutrition products, with 15 production facilities worldwide. Listed on the NYSE with $5 billion revenue in 2024, Perrigo has established significant market position through its unique store-brand business model, exceptional cost control capabilities, and pharmaceutical-grade quality standards.
Strengths: Perrigo's core strengths are its unique store-brand business model as key supplier to major global retailers with stable partnerships and strong customization capability; exceptional cost control through scaled production and supply chain optimization delivering significant value advantage; and pharmaceutical-grade stringent quality control ensuring reliable products meeting global compliance standards.
Weaknesses: The company has relatively low consumer brand recognition, relying mainly on retailer brands limiting end-market influence; faces intensifying market competition and pricing pressure; profitability remains vulnerable to raw material cost fluctuations; and encounters ongoing compliance challenges from evolving global health product regulations.

By-health Co., Ltd. is China's leading dietary supplements company, publicly traded on the Shenzhen Stock Exchange and headquartered in Zhuhai, Guangdong. With five production bases in China and an annual capacity of 5 billion supplement tablets/capsules, the company achieved RMB 8.5 billion (approximately $1.2 billion) in revenue in 2024. By-health maintains its dominant market position through comprehensive product portfolios, stringent quality control, and extensive distribution networks across China.
Strengths: By-health's core strengths are its absolute leadership in China's dietary supplement market with the top brand position, comprehensive multi-channel distribution network covering pharmacies and e-commerce platforms, and stringent quality control system with pharmaceutical-grade production standards.
Weaknesses: The company faces challenges including heavy reliance on the domestic market (95% of revenue) with limited international presence, intensifying competition in China's dietary supplement sector, and vulnerability to raw material cost fluctuations.

Herbalife Nutrition Ltd. is a global multi-level marketing nutrition company specializing in weight management products, nutritional supplements, and sports nutrition. Headquartered in Los Angeles and publicly traded on NYSE, it operates in 90 countries with 5 production facilities worldwide, generating $5 billion in revenue in 2024. The company maintains its market position through its distinctive direct selling model supported by approximately 4 million independent distributors and a comprehensive global distribution network.
Strengths: Herbalife's core strengths are its extensive global direct selling network with approximately 4 million distributors across 90 countries, strong focus on weight management products generating 40% of revenue, and vertically integrated manufacturing capabilities with five global production facilities.
Weaknesses: The company faces significant challenges including ongoing regulatory pressures and public controversies surrounding its multi-level marketing model, vulnerability to geopolitical risks across its extensive global operations, and intensifying competition in the nutrition and weight management sectors.

Meiji Holdings Co., Ltd. is a leading Japanese integrated food and pharmaceutical company headquartered in Tokyo. Operating in over 20 countries, its core businesses include dairy products, confectionery, nutritional foods, and pharmaceuticals, supported by 30+ global production bases. Listed on the Tokyo Stock Exchange with ¥1.2 trillion revenue in 2024, it maintains significant market presence in Japan's food and pharmaceutical sector through century-old brand heritage, dual technological expertise in food and pharmaceuticals, and stringent quality control.
Strengths: Meiji's core strengths are its unique dual expertise in food technology and pharmaceutical technology, creating significant synergies; industry-leading stringent quality control systems meeting both food and pharmaceutical standards; and over a century of brand heritage enjoying high consumer trust and recognition in Japan.
Weaknesses: The company faces excessive reliance on the domestic Japanese market, with about 85% of revenue from Japan, exposing it to market saturation and an aging population; its international expansion remains relatively limited with only 10% global coverage; and it contends with intensifying global competition and ongoing cost control pressures.